<p>Axel Heiser of AgResearch Ltd. in New Zealand proposes to develop a new type of tuberculosis vaccine that uses polyester biobeads produced in mycobacteria that carry a large repertoire of known and undiscovered antigens on their surface. This new technology combines the multiple antigenic benefits of live vaccines with a better safety profile and lower costs of production.</p>


Axel Heiser of AgResearch Ltd. in New Zealand proposes to develop a new type of tuberculosis vaccine that uses polyester biobeads produced in mycobacteria that carry a large repertoire of known and undiscovered antigens on their surface. This new technology combines the multiple antigenic benefits of live vaccines with a better safety profile and lower costs of production.